MHE Staff

The administration seems more interested in using Medicaid than Medicare as a tool for extending health insurance coverage to more Americans, notwithstanding all the debate about Medicare for all last year.

Fifty-three percent of Latinx and 49% of Black Medicare beneficiaries choose enrollment in Medicare Advantage; seeing average annual savings of $1,113 and $1,270, respectively, compared to Traditional Medicare.

In this final part of the MHE 2021 Pharmacy Survey, participants share their thoughts on which federal policies they favor as a way to curb drug prices and which policy is more likely to occur this year. MHE's annual pharmacy survey had over 225 respondents.

The nation's highest court has upheld the ACA three times.

In this part five series, participants give their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.

Former OptumRx executive, Gina Guinasso, J.D., is president of the newly named retail venture.

In this part four series, participants give their opinions on the biggest driver of specialty drug expenditures this year and what the most significant change in contracts between plan sponsors and PBMs could be in the near future. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.

According to the CDC, use of any contraception has remained stable in the United States. From 2015 to 2017, approximately 2 out of 3 girls and women ages 15 to 49 used some form of contraception,and a similar proportion did so from 2017 to 2019.

In this part three series, participants give their opinions on the most effective ways to reduce traditional and specialty pharmaceutical costs. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.

In this part two series, participants give their opinions on the lasting effects of the pandemic. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.

Respondents upbeat about COVID-19 vaccination. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.

According to a new West Health/Gallup survey, less than 20% of all Americans believe Medicare negotiation would hurt innovation or market competition, including a minority of Republicans.

Harvard researchers say, well, maybe.

Ten years ago, specialty accounted for 15% to 20% of the money spent on drugs, according to Prem Shah, executive vice president of specialty pharmacy and product innovation at CVS Health.

The Association of Community Cancer Centers launched the ACCC Community Oncology Research Institute, which builds on the organization's mission to close the gap in cancer research through optimal community oncology partnerships.

COVID-19 vaccination race among pharma giants results in brand value growth – Pfizer up 6%, AstraZeneca up 18%, and Sinopharm up 58%.

Acquisition to unite previously fragmented provider and payer insights to drive optimal healthcare outcomes.

Precision medicine is getting that much more precise. Today's FDA go-ahead is for a J&J drug that is designed to treat the 2% to 3% of NSCLC patients wiht EGFR exon 20 insertion mutations.

Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses his appreciation for telehealth and remote care, but feels over the next year or so we're going to be seeing more studies come out questioning if some telehealth is needed in certain areas. The discussion came from findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research.

Amy Abernethy, M.D., Ph.D., hematologist/oncologist and palliative medicine physician and former principal deputy commissioner of the FDA, discusses how the agency handled COVID-19 and what lessons learned will help going forward. Abernethy also addresses if she feels there are enough safeguards of the FDA's independence in place, and reflects on the open FDA commissioner position.

PBMs say exclusions are important for negotiating lower prices on behalf of health plans and members. Some payer and provider groups say they interfere with patient access to medicines.

"COVID. KNOW MORE," is an innovative, timely new initiative empowering Black Americans with the latest information, resources, and updates on COVID-19.

A 13% decline in the past year continues downward. Some of the decline might be explained by pandemic-related drop in healthcare utilization.

The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.

A recent study from American Accounting Association finds health insurance companies are overestimating costs associated with patient care to avoid triggering rebate provisions in the Affordable Care Act.

New starts fell off sharply last spring and the flu season "all but disappeared," according a summary of CVS Caremark's 2020 drug spend report.

Six-year plan to invest $11.5 billion with donor support to accelerate research and treatment worldwide for children with catastrophic diseases.

Centralized resource streamlines information sharing between health plans, Medicaid agencies and third-party app developers ahead of CMS Interoperability and Patient Access rule deadlines.

Biomarker status can help clinicians and patients make informed, personalized treatment decisions, whether the choice is an FDA-approved targeted therapy or a clinical trial.